Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout

Drug Discovery Today

Volumn 18, Issue 1-2, 2013, Pages 11-24

  Favoni, Roberto E ^a   Alama, Angela ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFATINIB; AZD 8931; BPI 2009H; CANERTINIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; ICOTINIB HYDROCHLORIDE; IRINOTECAN; LAPATINIB; NAVELBINE; NERATINIB; OXALIPLATIN; PACLITAXEL; PELITINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VINBLASTINE; XL 647;

CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CARCINOGENESIS; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; ONCOGENE; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; SURVIVAL RATE; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84871928651     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.07.011     Document Type: Review

References (96)

1. P.A. Wingo Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking J. Natl Cancer Inst. 91 1999 675 690
2. A. Jemal Global cancer statistics CA: Cancer J. Clin. 61 2011 69 90
3. Commonly diagnosed cancers worldwide. Cancer Research UK, April 2005. Retrieved 2008, http://info.cancerresearchhuk.org/cancerstats/geographic/world/ commoncancers/
4. American Cancer Society: Cancer Facts and Figures 2012. Atlanta, GA, http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-031941.pdf
5. E.M. Toloza Gene therapy for lung cancer J. Cell. Biochem. 99 2006 1 22
6. R.S. Herbst Lung cancer N. Engl. J. Med. 359 2008 1367 1380
7. R. Arrigada Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer N. Engl. J. Med. 350 2004 351 360
8. V.T. De Vita 7th edn Cancer Principles and Practice of Oncology Vol. 1 2005 Lippincott, Williams & Wilkins pp. 745-801
9. A. Clegg Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small cell lung cancer: a systematic review Thorax 57 2002 20 28
10. R.E. Favoni Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma Br. J. Pharmacol. 166 2012 532 553
11. H. Zhang Erb-B receptors: from oncogenes to targeted cancer therapies J. Clin. Invest. 117 2007 2051 2058
12. R.E. Favoni Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation Curr. Cancer Drug Target 2 2010 176 191
13. H. Yamamoto Impact of EGFR mutation analysis in non-small cell lung cancer Lung Cancer 63 2009 315 321
14. J.E. Dowell Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact Am. J. Med. Sci. 331 2006 139 149
15. L. Cheng Molecular pathology of lung cancer: key to personalized medicine Modern Pathol. 25 2012 347 369
16. F. Ciardiello, and G. Tortora EGFR antagonists in cancer treatment N. Engl. J. Med. 358 2008 1160 1174
17. O. Dassonville EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences Crit. Rev. Oncol. Hematol. 62 2007 53 61
18. F. Tan Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies Lung Cancer 76 2012 177 182
19. H. Shigematsu Somatic mutations of the HER2 kinase domain in lung adenocarcinoma Cancer Res. 65 2005 1642 1646
20. P.K. Jussi EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer Clin. Cancer Res. 14 2008 4275 4283
21. T. Kohno KIF5B-RET fusions in lung adenocarcinoma Nat. Med. 18 2012 375 377
22. K. Bergethon ROS1 rearrangements define a unique molecular class of lung cancers J. Clin. Oncol. 30 2012 863 870
23. M.F. Di Renzo Expression of the Met/HGF receptor in normal and neoplastic tissues Oncogene 6 1991 1997 2003
24. P.C. Ma c-Met: structure, functions and potential for therapeutic inhibition Cancer Met. Rev 22 2003 309 325
25. S. Yi Paracrine effects on hepatocyte growth factors/scatter factor on non-small cell lung carcinoma cell lines Br. J. Cancer 77 1998 2162 2170
26. B. Peruzzi, and D.P. Bottaro Targeting the cMet signaling pathway in cancer Clin. Cancer Res. 12 2006 3657 3660
27. N.A. Cipriani MET as a target for treatment of chest tumours Lung Cancer 63 2009 169 179
28. A. Gentile The Met tyrosine kinase receptor in development and cancer Cancer Metastasis Rev 27 2008 85 94
29. C. Boccaccio Invasive growth: a Met driven genetic programme for cancer and stem cells Nat. Rev. Cancer 6 2006 637 645
30. P.C. Ma Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer Cancer Res. 65 2005 1479 1488
31. P.C. Ma c-Met expression/activation, functions and mutation in non-small cell lung cancer Proc. Am. Assoc. Cancer Res. 45 2004 abs1875
32. K. Matsumoto, and T. Nakamura NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics Cancer Sci. 94 2003 321 327
33. T. Burgess Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors Cancer Res. 66 2006 1721 1729
34. Gordon, M.S. et al. (2007) Interim results from a first-in-human study with AMG102, a fully human monoclonal antibody that neutralizes hepatocyte growth factor (HGF), the ligand to c-Met receptor, in patients (pts) with advanced solid tumours. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 25 [18S (20 Suppl.)], 3551
35. T. Zohar A novel recombinant soluble splice variant of Met is a potent antagonist of the Hepatocyte Growth Factor/Scatter Factor-Met pathway Clin. Cancer Res. 14 2008 4612 4621
36. M. Mazzone An uncleavable form of pro-scatted factor suppresses the tumor growth and dissemination in mice J. Clin. Invest. 114 2004 1418 1432
37. S. Berthou The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants Oncogene 23 2004 5387 5393
38. G.A. Smolen Amplification of Met may identity a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA665752 Proc. Natl. Acad. Sci. U.S.A. 103 2006 2316 2321
39. N. Puri A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts Cancer Res. 67 2007 3529 3534
40. H.Y. Zou An orally available small-molecule inhibitor of c-Met, PF-2341066, exibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms Cancer Res. 67 2007 4408 4417
41. N. Munshi ARQ197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity Mol. Cancer Ther. 9 2010 1544 1553
42. S. Eathiraj Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ197 J. Biol. Chem. 286 2011 20666 20676
43. E. Gherardi Targeting MET in cancer: rationale and progress Nat. Rev. Cancer 12 2012 89 103
44. X. Liu Developing c-Met pathway inhibitors for cancer therapy: progress and challenges Trends Mol. Med. 16 2010 37 45
45. P.A. Janne Targeting Met with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical trial design EORTC-NCI-AACR Int Congress 2008 Abs552
46. F. Quian Inhibition of tumor cell growth, invasion and metastasis by Exel-2880 (XL-880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases Cancer Res. 69 2009 8009 8016
47. J.P. Eder Phase I experience with c-Met inhibitor XL880 administered orally to patients (pts) with solid tumors J. Clin. Oncol. 2518S 2007 Abs3526
48. T. Nakagawa E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models Cancer Sci. 101 2010 210 215
49. W. Wang Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth-factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer Clin. Cancer Res. 18 2012 1663 1671
50. S.G. Buchanan SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo Mol. Cancer Ther. 8 2009 3181 3190
51. J. Welsh c-Met inhibition radiosensitizes melanoma by inhibiting double strand DNA repair Int. J. Rad. Oncol. Biol. Phys. 66 2006 557 558
52. A. Morotti K252a inhibits the oncogenic properties of Met, the HGF receptor Oncogene 21 2002 4885 4893
53. A. Bardelli A peptide representing the carboxy-terminal tail of the Met receptor inhibits kinase activity and invasive growth J. Biol. Chem. 274 1999 29274 29281
54. P.A. Morton In vitro and in vivo activity of fully-human monoclonal antibody antagonists to c-Met protein tyrosine kinase Proc. Am. Assoc. Cancer Res. 43 2003 5604
55. R. Schwall Inhibition of c-Met activation by a one-armed antibody Proc. Am. Assoc. Cancer Res. 44 2004 1424
56. D. Li BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 27 2008 4702 4711
57. T. Shimamura Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2 in human NSCLC xenografts and in a transgenic mouse lung-cancer model J. Thor. Oncol. 2 2007 1 2
58. W. Wang Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study J. Clin. Oncol. 27 2009 2523 2529
59. H. Clevers The cancer stem cell: premises, promises and challenges Nat. Med. 17 2011 313 319
60. A. Alama Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies? Drug Discov. Today 17 2011 435 442
61. L. Pusztai Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma Cancer 104 2005 682 691
62. S.V. Holt Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055) Cancer Res. 72 2012 1804 1813
63. J. Meng Combination treatment with MEK and Akt inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo PLoS ONE 5 2010 e14124
64. C.X. Xu The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo PLoS ONE 6 2011 e20899
65. S.M. Wilhelm BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinase involved in tumor progression and angiogenesis Cancer Res. 64 2004 7099 7109
66. J.J. Wallin GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway Mol. Cancer Ther. 10 2011 2426 2436
67. J. Yuan PF-04691502, a potent and selective oral inhibitor of PI3K kinases with antitumor activity Mol. Cancer Ther. 10 2011 2189 2199
68. W. Fan MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents Cancer Res. 71 2011 4494 4505
69. P.N. King A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer nature medicine Nat. Med. 18 2012 521 531
70. R. Pirker Cetuximab plus chemotherapy in patients with advanced non-small cell lung cancer (FLEX): an open-label randomized phase III trial Lancet 373 2009 1525 1531
71. M.G. Kris Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 2003 2149 2158
72. R. Perez-Soler Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J. Clin. Oncol. 22 2004 3238 3247
73. P. Goldstraw Non-small-cell lung cancer Lancet 378 2011 1727 1740
74. V.I. Keedy American Society for Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR). Mutation testing for patients with advanced non-small cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy J. Clin. Oncol. 29 2011 2121 2127
75. C. Zhou Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802): a multi-centre, open-label, randomized, phase 3 study Lancet Oncol. 12 2011 735 742
76. F. Cappuzzo Erlotinib as maintenance treatment in advanced non-small cell lung cancer: a multicentre, randomized, placebo-controlled phase 3 study Lancet Oncol. 11 2010 521 529
77. M. Maemondo Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR N. Engl. J. Med. 362 2010 2380 2388
78. Q. Zhao Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors Lung Cancer 73 2011 195 202
79. R. Plummer A Phase I and pharmacokinetic (PK) study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor Eur. J. Cancer Suppl. 5 2007 108
80. V.A. Miller Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial Lancet Oncol. 2012 [Epub ahead of print]
81. J.C. Yang Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial Lancet Oncol. 2012 [Epub ahead of print]
82. Study to evaluate erlotinib with or without SNDX-275 in the treatment of patients with advanced NSCLC. Available at: http://clinicaltrials.gov/ct2/show/ NCT00602030 (accessed July 2012)
83. A.T. Shaw Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Lancet Oncol. 12 2011 1004 1012
84. G. Scagliotti ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development Eur. J. Cancer 48 2012 961 973
85. T. Sasaki A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors Cancer Res. 71 2011 6051 6060
86. J.V. Heymach Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer J. Clin. Oncol. 26 2008 165 166
87. R.B. Natale Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study J. Clin. Oncol. 27 2009 2523 2529
88. J.S. Lee Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind Phase III trial (ZEPHYR) J. Clin. Oncol. 30 2012 1114 1121
89. G.R. Blumenschein Jr. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, non-small cell lung cancer: a North Central Cancer Treatment Group Study J. Clin. Oncol. 25 2009 396s (abs7547)
90. M. Sattler The role of the c-Met pathway in lung cancer and the potential for targeted therapy Ther. Adv. Med. Oncol. 3 2011 171 184
91. K. Suda Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer Clin. Cancer Res. 16 2009 5489 5498
92. Y. Zhang XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC Drugs 13 2010 112 121
93. A. Garcia Phase I study of ARQ197, a selective inhibitor of the c-Met RTK in patients with metastatic solid tumors reaches recommended phase II dose J. Clin. Oncol. 2518S 2007 abs3525
94. J. von Pawel Rationale and design of MARQUEE: a Phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer Clin. Lung Cancer 2012 [Epub ahead of print]
95. L.V. Sequist Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer J. Clin. Oncol. 29 2011 3307 3315
96. G.V. Scagliotti Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer Clin. Cancer Res. 18 2012 1663 1671